<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04337567</url>
  </required_header>
  <id_info>
    <org_study_id>RS_RFCR_ELDPA_0120</org_study_id>
    <nct_id>NCT04337567</nct_id>
  </id_info>
  <brief_title>Radiofrequency Ablation Versus Balloon Cryoablation in Elderly Patients With Atrial Fibrillation</brief_title>
  <official_title>A Prospective Randomized Trial for the Comparison of Procedural Characteristics and Long-term Effects of Radiofrequency Ablation and Balloon Cryoablation in Elderly Patients With Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vivantes Netzwerk für Gesundheit GmbH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vivantes Netzwerk für Gesundheit GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study compares the procedural characteristics and effectivity of radiofrequency ablation
      and cryoablation in patients with atrial fibrillation that are 75 years or older.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Radiofrequency and cryoballon ablation have been shown to be comparable to each other in
      terms of safety and effectivity in patients with atrial fibrillation. However, elderly
      patients have been underrepresented in the previous studies. The number of older patients
      with atrial fibrillation is high and the number of who undergo an ablation procedure for
      atrial fibrillation increases steadily. This prospective randomized trial compares the
      effectivity (recurrency of atrial arrhythmias) and periprocedural characteristics of the two
      established ablation methods in patients who are 75 years or older.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2020</start_date>
  <completion_date type="Anticipated">January 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>atrial arrhythmia recurrence</measure>
    <time_frame>1 year</time_frame>
    <description>Number of Participants with recurrence of any atrial arrhythmia with a duration of 30 sec or longer 12 months after the ablative treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>procedural duration</measure>
    <time_frame>periprocedural</time_frame>
    <description>Duration of the whole procedure [min] inclusive preparation (from entrance to the EP lab till exit from the EP lab)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to wake-up after propofol withdrawal</measure>
    <time_frame>periprocedural</time_frame>
    <description>Time from withdrawal of propofole till patient awake and fully oriented (time, place, person)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>contrast medium dosis</measure>
    <time_frame>periprocedural</time_frame>
    <description>Amount of contrast medium used</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Propofoldosis</measure>
    <time_frame>periprocedural</time_frame>
    <description>Propofoldosis needed for sedation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>groin complications</measure>
    <time_frame>up to 3 months after dismission from the hospital</time_frame>
    <description>Number of Participants in each randomisation arm with groin complications (hematoma, av fistel, Aneuryma spurium, infection).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurological complications</measure>
    <time_frame>1 year</time_frame>
    <description>Number of Participants in each randomisation arm with transient ischemic attack, cerebral insult, cerebral haemorrhage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>vascular complications</measure>
    <time_frame>1 year</time_frame>
    <description>Number of Participants in each randomisation arm with deep vein thrombosis, peripheral embolism.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of hospital staying [days]</measure>
    <time_frame>1 year</time_frame>
    <description>duration of hospital staying: from admission till discharge in days</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Patients over 75 years_RF ablation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients randomized to receive pulmonary vein isolation by means of radiofrequency ablation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients over 75 years_ballon cryoablation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients randomized to receive pulmonary vein isolation by means of ballon cryoablation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>radiofrequency ablation</intervention_name>
    <description>ablative treatment as allocated to radiofrequency ablation</description>
    <arm_group_label>Patients over 75 years_RF ablation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>ballon cryoablation</intervention_name>
    <description>ablative treatment as allocated to ballon cryoablation</description>
    <arm_group_label>Patients over 75 years_ballon cryoablation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with recurrent symptomatic paroxysmal or persistent atrial fibrillation

          -  At the day of their inclusion in the study the patients have to have completed the
             75th year of life

        Exclusion Criteria:

          -  Dementia

          -  Presence of left atrial thrombus

          -  Left atrial volume&gt; 50 ml/m²

          -  Renal failure (GFR≤ 30 ml/min)

          -  Comorbidity with an expected survival of 12 months or less.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>75 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charalampos Kriatselis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vivantes Klinikum Neukölln</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Charalampos Kriatselis, MD</last_name>
    <phone>0049 30 15140663741</phone>
    <email>charalampos.kriatselis@vivantes.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michael Distler, MD</last_name>
    <phone>0049 30 130 142014</phone>
    <email>michael.distler@vivantes.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Vivantes Klinikum Neukölln</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charalampos Kriatselis, MD</last_name>
      <phone>0049 30 15140663741</phone>
      <email>charalampos.kriatselis@vivantes.de</email>
    </contact>
    <contact_backup>
      <last_name>Michael Distler, MD</last_name>
      <phone>0049 30 130 142014</phone>
      <email>michael.distler@vivantes.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>March 8, 2020</study_first_submitted>
  <study_first_submitted_qc>April 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 7, 2020</study_first_posted>
  <last_update_submitted>April 3, 2020</last_update_submitted>
  <last_update_submitted_qc>April 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vivantes Netzwerk für Gesundheit GmbH</investigator_affiliation>
    <investigator_full_name>Charalampos Kriatselis</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>ablative treatment of atrial fibrillation</keyword>
  <keyword>ballon cryoablation</keyword>
  <keyword>radiofrequency ablation</keyword>
  <keyword>elderly patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

